Skip to main content
Equibles

Jefferies Financial Group Inc.

Position in SLS — SELLAS Life Sciences Group, Inc.

CIK 96223 NEW YORK, NY
Back to SLS Full portfolio

Position in SLS

as of Jun 30, 2026 · filed Aug 17, 2026
Position Value
$2,958,774
+$2,920,697 QoQ
Shares Held
200,459
+1884.7% QoQ
Ownership
0.099%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#35
of 192 holders
Holding Since
Dec 2025
2 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in SLS Over Time

Shares Held

Position Value (USD)

Derivatives in SLS

reported options exposure · as of Jun 30, 2026
CallValue
$0
CallShares
0
PutValue
$2,953,476
PutShares
200,100

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Jefferies Financial Group Inc. holds $677,219,224 across 66 Biotechnology names. SLS ranks #29 (0.4% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 PTCT
Ptc Therapeutics, Inc.
 1,357,042 $110,693,915
2 URGN
UroGen Pharma Ltd.
 2,199,652 $80,947,193
3 IMTX
Immatics N.V.
 6,506,802 $65,913,904
4 TNGX
Tango Therapeutics, Inc.
 2,010,534 $62,849,292
5 CGON
CG Oncology, Inc.
 769,947 $54,704,734
6 ARGX
Argenx SE
 45,068 $41,812,738
7 RARE
Ultragenyx Pharmaceutical Inc.
 929,626 $31,040,212
8 BMRN
Biomarin Pharmaceutical Inc
 466,258 $26,679,282

All Filings in SLS

Export CSV
4 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $2,958,774 200,459
2026-06-30 $2,953,476 200,100
2025-12-31 $38,077 10,100
2025-12-31 $38,077 10,100